Test of envafolimab plus lenvatinib for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have advanced or metastatic solid cancer that has progressed after standard treatment, or you have no effective options (some groups are specific to lung or kidney cancers).
- You must not be able to have surgery for the cancer in some groups (for the kidney cancer portion), and you must have at least one measurable tumor spot on scans.
- You need suitable biopsy or tumor tissue samples from before starting certain treatments, and your body systems must work well enough for study medicines.
- Your overall strength level must meet specific limits (for example, ECOG 0–1 or KPS at least 70, depending on the group).
- You must be able to provide signed informed consent and have an expected lifespan of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of a drug injected directly into the lung tumor and a systemic antibody treatment (likely immunotherapy) for advanced non-small cell lung cancer. It may help if you have a collapsed lung and your cancer has not responded to prior treatment.
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.